Kalaris Therapeutics Inc
KLRSNASDAQHealthcare● Active
$4.17
$-0.27(-6.08%)
Market Cap$77990242
P/E Ratio—
52W High$11.88
52W Low$2.14
Kalaris Therapeutics Inc (KLRS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KLRS · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.46
Est. -$0.52 · +11.5%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
KLRS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.50 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.52 | -$0.46 | +11.5% | — | — | — |
| ▲ Q1 FY2026 | Mar 17, 2026 | -$0.56 | -$0.44 | +21.4% | — | — | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.66 | -$0.64 | +3.0% | — | — | — |
| ▼ Q3 FY2025 | Aug 13, 2025 | -$0.51 | -$0.61 | -19.6% | — | — | — |
| ▼ Q2 FY2025 | May 14, 2025 | -$0.78 | -$2.52 | -223.1% | — | — | — |
| ▼ Q1 FY2025 | Mar 7, 2025 | -$2.76 | -$3.64 | -31.8% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.14 | -$0.04 | +71.4% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.50
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.46
EPS Est.
-$0.52
EPS Surpr.
+11.5%
Revenue
—
Q1 FY2026
Mar 17, 2026Beat
EPS Actual
-$0.44
EPS Est.
-$0.56
EPS Surpr.
+21.4%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.64
EPS Est.
-$0.66
EPS Surpr.
+3.0%
Revenue
—
Q3 FY2025
Aug 13, 2025Miss
EPS Actual
-$0.61
EPS Est.
-$0.51
EPS Surpr.
-19.6%
Revenue
—
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$2.52
EPS Est.
-$0.78
EPS Surpr.
-223.1%
Revenue
—
Q1 FY2025
Mar 7, 2025Miss
EPS Actual
-$3.64
EPS Est.
-$2.76
EPS Surpr.
-31.8%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.04
EPS Est.
-$0.14
EPS Surpr.
+71.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.47 | $-0.47 | $-0.47 | 2 |
| Q3 FY2027 | $-0.40 | $-0.40 | $-0.40 | 2 |
| Q2 FY2027 | $-0.38 | $-0.38 | $-0.38 | 2 |
| Q1 FY2027 | $-0.53 | $-0.53 | $-0.53 | 2 |
| Q4 FY2026 | $-0.53 | $-0.53 | $-0.53 | 4 |
| Q3 FY2026 | $-0.55 | $-0.49 | $-0.37 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +11.5% | $4.73 | $4.79 | +1.27% |
| ▲ Q1 FY2026 | Mar 17, 2026 | +21.4% | $8.81 | $8.52 | -3.29% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +3.0% | $5.07 | $4.96 | -2.17% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -19.6% | $2.49 | $2.28 | -8.43% |
| ▼ Q2 FY2025 | May 14, 2025 | -223.1% | $3.25 | $3.38 | +4.00% |
| ▼ Q1 FY2025 | Mar 7, 2025 | -31.8% | $9.73 | $9.87 | +1.44% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +71.4% | $390.93 | $286.45 | -26.73% |
| ▲ Q2 FY2024 | Jun 30, 2024 | +52.2% | $382.63 | $386.17 | +0.93% |
Q2 FY2026+1.27%
Report Date
May 12, 2026
EPS Beat/Miss
+11.5%
Price Before
$4.73
Price After
$4.79
Q1 FY2026-3.29%
Report Date
Mar 17, 2026
EPS Beat/Miss
+21.4%
Price Before
$8.81
Price After
$8.52
Q4 FY2025-2.17%
Report Date
Nov 12, 2025
EPS Beat/Miss
+3.0%
Price Before
$5.07
Price After
$4.96
Q3 FY2025-8.43%
Report Date
Aug 13, 2025
EPS Beat/Miss
-19.6%
Price Before
$2.49
Price After
$2.28
Q2 FY2025+4.00%
Report Date
May 14, 2025
EPS Beat/Miss
-223.1%
Price Before
$3.25
Price After
$3.38
Q1 FY2025+1.44%
Report Date
Mar 7, 2025
EPS Beat/Miss
-31.8%
Price Before
$9.73
Price After
$9.87
Q4 FY2024-26.73%
Report Date
Nov 12, 2024
EPS Beat/Miss
+71.4%
Price Before
$390.93
Price After
$286.45
Q2 FY2024+0.93%
Report Date
Jun 30, 2024
EPS Beat/Miss
+52.2%
Price Before
$382.63
Price After
$386.17
Avg Beat Reaction-6.00%
Avg Miss Reaction-1.00%
Beat Rate5 / 8 quarters
Largest Move-26.73% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KLRS ends December
Kalaris Therapeutics Inc (KLRS) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.46 — beating the analyst consensus of $-0.52 by +11.5%. KLRS has beaten EPS estimates for 3 consecutive quarters. The next KLRS earnings date is expected around September 1, 2026.
Each quarter, investors track KLRS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KLRS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KLRS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KLRS earnings · 5 questionsKalaris Therapeutics Inc's next earnings report is expected around September 1, 2026. KLRS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KLRS historically reports after market close (AMC).
KLRS earnings datewhen is KLRS earningsKLRS next earnings datewhen does KLRS report earningsKLRS earnings calendar
▸ Source: FMP · Kalaris Therapeutics Inc SEC filings · US GAAP · Kalaris Therapeutics Inc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026